PTN Palatin Technologies, Inc. Comm

0.36
+0  (1%)
Previous Close 0.36
Open 0.37
Price To book 0.00
Market Cap 50.07M
Shares 137,947,000
Volume 2,218,759
Short Ratio 4.38
Av. Daily Volume 2,070,260

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due early 2018.
Rekynda
Female sexual dysfunction (FSD)
Phase 2 planned for 1H 2017
PL-3994
Heart failure

Latest News

  1. Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House
  2. Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
  3. Palatin Technologies To Present At The 29th Annual ROTH Conference
  4. AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
  5. Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers
  6. AMAG Pharmaceuticals Inks $60M Drug Deal
  7. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
  8. Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™
  9. Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?
  10. Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
  11. AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal
  12. AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
  13. Why AMAG Pharmaceuticals, Inc. Is Falling Today
  14. How CytRx Corporation (CYTR) Stacks Up Against Its Peers
  15. Palatin Technologies Closes on $16.5 Million Financing
  16. Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q1, 2017 By the Numbers : December 1, 2016
  17. Palatin Technologies Announces Pricing of Public Offering of Common Stock and Warrants
  18. Palatin Technologies Announces Proposed Public Offering of Common Stock and Warrants

SEC Filings

  1. CT ORDER - Confidential treatment order 17667211
  2. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17602637
  3. 10-Q - Quarterly report (Sections 13 or 15(d)) 17593538
  4. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17587846
  5. 8-K - Current report 17584693
  6. 8-K - Current report 17570367
  7. 8-K - Current report 17515868
  8. 424B5 - Prospectus (Rule 424(b)(5)) 162029414
  9. 8-K - Current report 162029082
  10. 424B5 - Prospectus (Rule 424(b)(5)) 162025472